0001209191-17-057661.txt : 20171020
0001209191-17-057661.hdr.sgml : 20171020
20171020171228
ACCESSION NUMBER: 0001209191-17-057661
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171012
FILED AS OF DATE: 20171020
DATE AS OF CHANGE: 20171020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Crowley John F
CENTRAL INDEX KEY: 0001400973
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33497
FILM NUMBER: 171147574
MAIL ADDRESS:
STREET 1: C/O AMICUS THERAPEUTICS, INC.
STREET 2: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMICUS THERAPEUTICS INC
CENTRAL INDEX KEY: 0001178879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200422823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: (609) 662-2000
MAIL ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2017-10-12
2017-10-17
0
0001178879
AMICUS THERAPEUTICS INC
FOLD
0001400973
Crowley John F
C/O AMICUS THERAPEUTICS, INC.
1 CEDAR BROOK DRIVE
CRANBURY
NJ
08512
1
1
0
0
Chairman & CEO
Common Stock
2017-10-12
4
M
0
380000
14.2495
A
708001
D
Common Stock
2017-10-12
4
S
0
380000
14.2495
D
328001
D
Common Stock
2017-10-13
4
M
0
22160
14.7503
A
350161
D
Common Stock
2017-10-13
4
S
0
22160
14.7503
D
328001
D
Common Stock
2017-10-16
4
M
0
47135
14.75
A
375136
D
Common Stock
2017-10-16
4
S
0
47135
14.75
D
328001
D
Common Stock
64895
D
Stock Options (right to buy)
6.45
2017-10-12
4
M
0
5783
0.00
D
2016-02-15
2022-02-15
Common Stock
5783
131024
D
Stock Options (right to buy)
4.38
2017-10-12
4
M
0
13622
0.00
D
2016-06-04
2022-06-04
Common Stock
13622
136378
D
Stock Options (right to buy)
3.53
2017-10-12
4
M
0
3462
0.00
D
2017-01-28
2023-01-28
Common Stock
3462
161538
D
Stock Options (right to buy)
2.52
2017-10-12
4
M
0
165000
0.00
D
2017-06-18
2023-06-18
Common Stock
165000
0
D
Stock Options (right to buy)
3.19
2017-10-12
4
M
0
192133
0.00
D
2015-01-03
2024-01-03
Common Stock
192133
20972
D
Stock Options (right to buy)
3.53
2017-10-13
4
M
0
22160
0.00
D
2017-01-28
2023-01-28
Common Stock
22160
139378
D
Stock Options (right to buy)
3.53
2017-10-16
4
M
0
47135
0.00
D
2017-01-28
2023-01-28
Common Stock
47135
92243
D
The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This Form 4 amendment corrects the reporting person's Remarks from the originally filed Form 4. The Remarks should read as follows: Shares were sold to fund the "Megan K. Crowley 2016 Special Needs Trust", a trust for the benefit of Mr. Crowley's child, with the balance of the proceeds used for general estate planning purposes. The total shares sold represented less than 14% of Mr. Crowley's holdings of securities of the company and after these transactions, Mr. Crowley's percentage of shares beneficially owned is 1% of the company's outstanding shares.
/s/ John F. Crowley
2017-10-20